We’re in this together, investing in bold ideas and the founders brave enough to chase them.
The posts and insights we share here reflect our collective hunch – the future’s full of unknowns and no one can predict the future. But with shared perspectives and a little optimism, we just might back the ones who get it right.
Richard Moore on right-sized angel due diligence in 2026: how AI, ESVCLP co-investment, and the deep dive call have moved the threshold for “enough.”
The CGT changes matter enough to angel investors and founders of early stage companies that I felt compelled to submit the following to the Senate Economics Legislation Committee.
Angel pitches are being read twice as AI changes how both sides of the table prepare. The bar hasn’t moved but the speed at which it gets applied has.
Richard Moore describes his unexpected angel investment framework, a falsification test that focuses his analysis and guides whether he considers a deal investable.
Mathematician turned angel investor, Richard Moore, explains why the same tool that solved derivatives pricing is the right way to think about angel portfolio construction.
Why the problem statement is the most important slide in any angel pitch and how angels separate fundable niches from society-sized traps, with regtech as the elegant exception.
MooCoo backs indi, the medtech company putting parents and allied health professionals on the same page through a child’s developmental journey.
Australia’s smelters are closing one by one. Bailouts won’t reverse it, and politics won’t either. Here’s where the catalyst comes from and what angels should watch for.
The sentences that will matter most in the AI S-1s won’t be the ones everyone reads. What an angel investor brings to the room, and why the AI vintage will need it.
Why AI-driven unemployment will not end in depression, the savings generated by productivity improvements, and why that matters for angel investors.
MooCoo backs Enaxiom, the Australian startup turning data centre cooling on its head, cutting energy consumption and generating ultra-pure water as a by-product.
Why the smartest consumer product founders build patent commercialisation companies, not manufacturing empires, and why angels who understand the difference back more winners.
The more capable AI becomes at analysing deals, the clearer it becomes that analysis was never the hard part: conviction is. Here’s why the final choice is still human-led.
MooCoo backs Wellumio, the New Zealand medtech company bringing MRI-quality stroke diagnostics to the bedside and better outcomes to patients.
In 2000, a simple formula revealed the internet’s commercial structure. Here’s what 600,000 domain names taught one angel investor and why it still matters.
Why micro nuclear, Australian uranium enrichment, and angel investing are about to collide.
